Tectonic Therapeutic grants 21,000 options to CSO

Tectonic Therapeutic’s Chief Scientific Officer received a 21,000-share stock option grant with staged vesting and a $29.92 exercise price.

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. (TECX) reported that Chief Scientific Officer Peter McNamara received a grant of stock options for 21,000 shares of common stock on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. One-eighth of the options vest on September 3, 2026, with the remainder vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service. No transactions were made under a Rule 10b5-1 trading plan, and McNamara now holds 21,000 options directly from this award.

Insider Trade Summary

Grant/Award: 21,000 shares

Grant/Award 1 txn

Insider McNamara Peter

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1	21,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 21,000 contracts (Direct)

Footnotes (1)

1. F1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Stock options granted: 21,000 options Exercise price: $29.92 per share Options held after transaction: 21,000 options +3 more

6 metrics

Stock options granted 21,000 options Grant to Chief Scientific Officer Peter McNamara on September 3, 2026

Exercise price $29.92 per share Exercise price for the 21,000 stock options granted September 3, 2026

Options held after transaction 21,000 options Total stock options held directly by Peter McNamara following the reported grant

Expiration date September 2, 2036 Expiration of the stock options granted to Peter McNamara

Initial vesting portion 1/8 of options Vests on September 3, 2026, from the 21,000-option grant

Remaining vesting period 42 monthly installments Equal monthly vesting installments beginning October 3, 2026

Key Terms

Employee Stock Option, vesting, installments, expiration date

4 terms

Employee Stock Option financial

"Employee Stock Option (Right to Buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

vesting financial

"the shares subject to the option vest on September 3, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

installments financial

"the remaining shares subject to the option vesting in the following 42 equal monthly installments"

Installments are a series of scheduled partial payments that together cover a larger amount owed or due, like paying for a purchase or loan in weekly or monthly pieces rather than all at once. For investors, installments matter because they change when cash moves between parties, affect a company’s or counterparty’s short-term cash flow and risk of missed payments, and can influence valuation or perceived financial stability much like spreading the cost of a car over monthly payments.

expiration date financial

"expire on September 2, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What insider transaction did TECX disclose for Chief Scientific Officer Peter McNamara?

Tectonic Therapeutic disclosed that Chief Scientific Officer Peter McNamara received a grant of 21,000 stock options on September 3, 2026, giving him the right to buy common shares at a fixed exercise price, subject to the vesting schedule described in the filing.

What is the exercise price of the stock options granted to the TECX Chief Scientific Officer?

The stock options granted to Chief Scientific Officer Peter McNamara have an exercise price of $29.92 per share. This is the price at which he may purchase Tectonic Therapeutic common stock upon exercising the vested options.

How do the 21,000 TECX stock options granted to Peter McNamara vest?

The grant vests over time: one-eighth of the options vest on September 3, 2026, and the remaining shares vest in 42 equal monthly installments starting October 3, 2026, contingent on his continued service to Tectonic Therapeutic on each vesting date.

When do the newly granted TECX stock options to Peter McNamara expire?

The stock options granted to Peter McNamara expire on September 2, 2036. Any unexercised options after that expiration date will no longer be exercisable according to the terms disclosed.

How many TECX stock options does Peter McNamara hold after this transaction?

After this grant, Peter McNamara holds 21,000 stock options directly. This total corresponds to the full number of options covered by the September 3, 2026 award reported in the filing.

Were the TECX option transactions for Peter McNamara made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan was reported in connection with this stock option grant to Chief Scientific Officer Peter McNamara.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:45 PM Accepted by SEC EDGAR 09/08/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McNamara Peter

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$29.92	09/03/2026		A		21,000		(1)	09/02/2036	Common Stock	21,000	$0	21,000	D

Explanation of Responses:

1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)